Genetic recombination

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

Retrieved on: 
Wednesday, June 22, 2022
MSD, Security (finance), RNA, DNA repair, Genetics, LinkedIn, Cdx, MD, Health, Institute of technology, Merck & Co., Genome, Neoplasm, Time, Prostate, MSI, Review, Agriculture, Technical University of Munich, Technology, Reproductive health, Cancer, Workflow, Form 10-K, DNA, YouTube, NASDAQ, HRD, CGP, Twitter, Cell, TSO, Microsatellite instability, MYGN, NGS, Biomarker, Ovarian cancer, Illumina, Inc., Patient, U.S. Securities and Exchange Commission, Instagram, TMB, Genetic recombination, Gene, Research, Precision medicine, Efficiency, Myriad Genetics, 500, Partnership, Biopsy, SAN, Breast, Pharmaceutical industry, Medical imaging, Vaccine, Illumina, Merck, EU, Facebook

SAN DIEGO, June 22, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test, codeveloped with Merck (known as MSD outside the United States and Canada). The research test builds upon Illumina's commitment to broadly enable comprehensive genomic profiling and enhance research critical to realizing precision medicine in oncology. The test adds assessment of a new genomic signature to the distributed, market leading TruSight™ Oncology 500 assay. It will be available globally, excluding the United States and Japan and will enable researchers to unlock deeper insights about the tumor genome by identifying genetic mutations used in the evaluation of homologous recombination deficiency (HRD).

Key Points: 
  • The research test builds upon Illumina's commitment to broadly enable comprehensive genomic profiling and enhance research critical to realizing precision medicine in oncology.
  • The test adds assessment of a new genomic signature to the distributed, market leading TruSight Oncology 500 assay.
  • It will be available globally, excluding the United States and Japan and will enable researchers to unlock deeper insights about the tumor genome by identifying genetic mutations used in the evaluation of homologous recombination deficiency (HRD).
  • Combining HRD assessment with TruSight Oncology 500 in one workflow will unlock the most comprehensive view of the tumor genome, while maintaining efficiency in the lab."

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

Retrieved on: 
Wednesday, June 22, 2022
MSD, Security (finance), RNA, DNA repair, Genetics, LinkedIn, Cdx, MD, Health, Institute of technology, Merck & Co., Genome, Neoplasm, Time, Prostate, MSI, Review, Agriculture, Technical University of Munich, Technology, Reproductive health, Cancer, Workflow, Form 10-K, DNA, YouTube, NASDAQ, HRD, CGP, Twitter, Cell, TSO, Microsatellite instability, MYGN, NGS, Biomarker, Ovarian cancer, Illumina, Inc., Patient, U.S. Securities and Exchange Commission, Instagram, TMB, Genetic recombination, Gene, Research, Precision medicine, Efficiency, Myriad Genetics, 500, Partnership, Biopsy, SAN, Breast, Pharmaceutical industry, Medical imaging, Vaccine, Illumina, Merck, EU, Facebook

SAN DIEGO, June 22, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test, codeveloped with Merck (known as MSD outside the United States and Canada). The research test builds upon Illumina's commitment to broadly enable comprehensive genomic profiling and enhance research critical to realizing precision medicine in oncology. The test adds assessment of a new genomic signature to the distributed, market leading TruSight™ Oncology 500 assay. It will be available globally, excluding the United States and Japan and will enable researchers to unlock deeper insights about the tumor genome by identifying genetic mutations used in the evaluation of homologous recombination deficiency (HRD).

Key Points: 
  • The research test builds upon Illumina's commitment to broadly enable comprehensive genomic profiling and enhance research critical to realizing precision medicine in oncology.
  • The test adds assessment of a new genomic signature to the distributed, market leading TruSight Oncology 500 assay.
  • It will be available globally, excluding the United States and Japan and will enable researchers to unlock deeper insights about the tumor genome by identifying genetic mutations used in the evaluation of homologous recombination deficiency (HRD).
  • Combining HRD assessment with TruSight Oncology 500 in one workflow will unlock the most comprehensive view of the tumor genome, while maintaining efficiency in the lab."

AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

Retrieved on: 
Monday, April 18, 2022
MSD, Cdx, SZSE, Commercialization, Party, NGS, GLOBE, Patient, Biomarker, PARP, Breast cancer, BRCA, AstraZeneca, Prostate cancer, Genetic recombination, Partnership, Breast, HRR, Prostate, Cancer, Pharmaceutical industry, EU

The master collaboration agreement enables the Parties to collaborate in the development and commercialization of AmoyDx assays that may cover any type of indication or biomarker for companion diagnostic (CDx) use with AstraZeneca medicines globally.

Key Points: 
  • The master collaboration agreement enables the Parties to collaborate in the development and commercialization of AmoyDx assays that may cover any type of indication or biomarker for companion diagnostic (CDx) use with AstraZeneca medicines globally.
  • Li-Mou Zheng, Ph.D., Founder and Chairman of AmoyDx, commented: We are very pleased to announce today that we are further developing our partnership with AstraZeneca by entering into a master collaboration agreement.
  • Amoy Diagnostics Co., Ltd.(SZSE: 300685)is a leading biotech company which pioneered the development and commercialization of cancer diagnostics inChina.
  • AmoyDx has a market-leading portfolio of molecular tests and is the therapy diagnostics partner for several major multinational pharmaceutical companies offering precision therapies for cancer.

SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research

Retrieved on: 
Monday, March 14, 2022
Sophia, Genetics, Genomics, Twitter, NGS, Pathology, Sophia Genetics, IDX, Software as a service, Research, Machine learning, HRD, AI, Instagram, LLC, U.S. Securities and Exchange Commission, Health, Precision medicine, Lung cancer, GENETICS, Genetic recombination, Artificial intelligence, Leadership, Patient, AVA, Solution, Technology, Intelligence, CEO, Diagnosis, Radiology, Forward-looking statement, LinkedIn, Medical device, Pharmaceutical industry, Medical imaging

BOSTON, ALISO VIEJO, Calif. and LAUSANNE, Switzerland, March 14, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced today that they signed a letter of intent to collaborate in the co-development of novel genomic applications and commercialization of multi-modal applications. Together, the companies aim to expand next-generation sequencing (NGS) research for cancer care and develop new multi-modal data streams to improve patient outcomes. The companies expect to enter into a definitive collaboration agreement following further discussion.

Key Points: 
  • BOSTON, ALISO VIEJO, Calif. and LAUSANNE, Switzerland, March 14, 2022 /PRNewswire/ --SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced today that they signed a letter of intent to collaborate in the co-development of novel genomic applications and commercialization of multi-modal applications.
  • Assessments can leverage TumorNEXT-HRD, a product of Ambry Genetics, a subsidiary of REALM IDx.
  • SOPHiA GENETICS and REALM IDx also expect to explore the potential for increasing diagnostic insights by combining Ambry Genetics' Variant Assessment database (AVA) with SOPHiA GENETICS' SOPHiA DDM (Data-Driven Medicine) platform for HRD detection.
  • SOPHiA GENETICS and REALM IDx also share an interest in bringing together genomics, radiology, and pathology data, combined with artificial intelligence, to generate actionable insights.

Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

Retrieved on: 
Monday, March 14, 2022
Association for Molecular Pathology v. Myriad Genetics, Inc., University, Risk, U.S. Securities and Exchange Commission, FACOG, Health, Precision medicine, Private Securities Litigation Reform Act, HIV disease progression rates, Prequel, Industry, Minimal, Genome, Fast Company, FDA, Mutation, Intermountain Healthcare, Sumathi Best Television Current Reporting Award, Genetic recombination, Ovarian cancer, GLOBE, Patient, Oncology, NASDAQ, Myriad Genetics, Clinical trial, Physician, SALT, Research, Gynecologic Oncology (journal), FACS, Cancer, Genomics, MYGN, Security (finance), Solution, MRD, Genetics, Intermountain, Breast, Liquid biopsy, HRD, M.D, Geography, Genetic testing, Technology, COVID-19, Pharmaceutical industry, Medical imaging, Myriad

Precise Oncology Solutions includes Myriads new Precise Tumor Molecular Profile Test, developed in collaboration with Intermountain Precision Genomics, leading healthcare providers, and industry partners.

Key Points: 
  • Precise Oncology Solutions includes Myriads new Precise Tumor Molecular Profile Test, developed in collaboration with Intermountain Precision Genomics, leading healthcare providers, and industry partners.
  • The information gathered from each of these tests are critical elements to help navigate each patients unique cancer treatment path.
  • Myriad is also introducing a new Precise Treatment Registry that combines germline, somatic and HRD genetic data with patient outcomes to accelerate the pace of precision cancer research and equitable advancements in patient care.
  • Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.

SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research

Retrieved on: 
Monday, March 14, 2022
Sophia, Genetics, Genomics, Twitter, NGS, Pathology, Sophia Genetics, IDX, Software as a service, Research, Machine learning, HRD, AI, Instagram, LLC, U.S. Securities and Exchange Commission, Health, Precision medicine, Lung cancer, GENETICS, Multimedia, Genetic recombination, Artificial intelligence, Leadership, Patient, AVA, Solution, Technology, Intelligence, CEO, Diagnosis, Radiology, Forward-looking statement, LinkedIn, Medical device, Pharmaceutical industry, Medical imaging

BOSTON, ALISO VIEJO, Calif. and LAUSANNE, Switzerland, March 14, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced today that they signed a letter of intent to collaborate in the co-development of novel genomic applications and commercialization of multi-modal applications. Together, the companies aim to expand next-generation sequencing (NGS) research for cancer care and develop new multi-modal data streams to improve patient outcomes. The companies expect to enter into a definitive collaboration agreement following further discussion.

Key Points: 
  • BOSTON, ALISO VIEJO, Calif. and LAUSANNE, Switzerland, March 14, 2022 /PRNewswire/ --SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced today that they signed a letter of intent to collaborate in the co-development of novel genomic applications and commercialization of multi-modal applications.
  • Assessments can leverage TumorNEXT-HRD, a product of Ambry Genetics, a subsidiary of REALM IDx.
  • SOPHiA GENETICS and REALM IDx also expect to explore the potential for increasing diagnostic insights by combining Ambry Genetics' Variant Assessment database (AVA) with SOPHiA GENETICS' SOPHiA DDM (Data-Driven Medicine) platform for HRD detection.
  • SOPHiA GENETICS and REALM IDx also share an interest in bringing together genomics, radiology, and pathology data, combined with artificial intelligence, to generate actionable insights.

Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7

Branches of biology, Biology, DNA repair, Cellular processes, Molecular genetics, Mutation, Senescence, Homologous recombination, DNA mismatch repair, Genetic recombination, Synthetic lethality

Cellworks Omics Biology Model (CBM) analysis can identify genetic signatures associated with therapy response and non-response for AML patients with Monosomy 7 in advance of treatment, which in turn can inform therapy planning and improve patient outcomes.

Key Points: 
  • Cellworks Omics Biology Model (CBM) analysis can identify genetic signatures associated with therapy response and non-response for AML patients with Monosomy 7 in advance of treatment, which in turn can inform therapy planning and improve patient outcomes.
  • Cellworks CBM analysis identified other genomic alterations that determine chemotherapy response, which can enable a personalized approach to therapy.
  • Cellworks CBM analysis identified other genomic alterations that determine chemotherapy response, including DNA repair deficiency genes, mismatch repair (MMR), and homologous recombination repair (HRR) genes.
  • On the other hand, Cellworks CBM analysis identified genetic signatures associated with a 100% remission rate from AML induction therapy despite the presence of (-7).

Burning Rock Announces In-Licensing of Myriad myChoice® Tumor Testing in China

Retrieved on: 
Monday, November 16, 2020
Branches of biology, Biology, Medical genetics, Myriad Genetics, HRD, Homologous recombination, Genetic recombination

GUANGZHOU, China, Nov. 15, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock) today announced that it entered into a development and commercialization agreement with Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad) which will bring myChoice tumor testing for homologous recombination deficiency, or HRD, to China.

Key Points: 
  • GUANGZHOU, China, Nov. 15, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock) today announced that it entered into a development and commercialization agreement with Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad) which will bring myChoice tumor testing for homologous recombination deficiency, or HRD, to China.
  • Through the partnership with Myriad, Burning Rock will perform myChoice HRD testing in China for collaborative drug development studies and for clinics.
  • The myChoice test is highly synergistic with Burning Rock's existing testing platforms.
  • Through close collaboration with Burning Rock in China, we are bringing the clinical benefits of myChoice testing to additional markets and patients, advancing personalized treatment for patients around the world, said Nicole Lambert, president of Myriad Genetic Laboratories.

Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team

Retrieved on: 
Tuesday, July 7, 2020
Branches of biology, Biology, DNA repair, RAD51, Cellular processes, Molecular genetics, Synthetic lethality, Genetic recombination, RAD54B

Additionally, the company announced the appointment of three senior executives, all with extensive pharmaceutical and biotechnology leadership experience.

Key Points: 
  • Additionally, the company announced the appointment of three senior executives, all with extensive pharmaceutical and biotechnology leadership experience.
  • Inhibiting RAD51-mediated homologous recombination in these cancer cells limits their ability to self-repair, leading to overwhelming DNA damage and ultimately, self-destruction a therapeutic effect known as synthetic lethality.
  • These findings support the broad potential for CYT-0851 to address the high unmet clinical need across various cancers and stages.
  • Cyteir Therapeutics, Cyteir, and associated logos are trademarks of Cyteir Therapeutics, Inc.

Never-before-seen DNA recombination in the brain linked to Alzheimer's disease

Retrieved on: 
Monday, November 26, 2018
Biology, Alzheimer's disease, Neuroscience, Medicine, Neurochemistry, Amyloidosis, Abnormal psychology, RTT, Amyloid precursor protein, Genetic recombination, Alzheimer's disease research, Neurogenomics

"Gene recombination was discovered as both a normal process for the brain and one that goes wrong in Alzheimer's disease."

Key Points: 
  • "Gene recombination was discovered as both a normal process for the brain and one that goes wrong in Alzheimer's disease."
  • One hundred percent of the Alzheimer's disease brain samples contained an over-abundance of distinct APP gene variants, compared to samples from normal brains.
  • Although found in a mosaic pattern, the identical APP variants were observed in the most common form of Alzheimer's disease, further linking gene recombination in neurons to disease.
  • "These findings may fundamentally change how we understand the brain and Alzheimer's disease," says Chun.